{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:15:45Z","timestamp":1740176145647,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K08809"],"award-info":[{"award-number":["18K08809"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["JA Clin Rep"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>There have been only few reports on butylscopolamine-induced anaphylaxis despite its global usage as an anticholinergic agent for approximately 70\u2009years. We present a case of anaphylaxis caused by butylscopolamine.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 63-year-old woman underwent gastrointestinal endoscopic examination. She developed facial cyanosis and hypoxia after intravenous administration of butylscopolamine 10\u2009mg, and her blood pressure was unmeasurable. Her hemodynamic condition recovered after a total of 0.6\u2009mg adrenaline and bolus administration of 100\u2009mg hydrocortisone. One hour after the onset of hypotension, both plasma histamine and serum tryptase were remarkably elevated to 271.7\u2009nmol\/L and 174\u2009\u03bcg\/L, respectively. Skin tests performed 47\u2009days after anaphylaxis showed a positive result only for butylscopolamine among the exposed agents, which was confirmed by basophil activation tests using CD203c and CD63 as markers.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Butylscopolamine has the potential to cause severe anaphylaxis; hence, identification of the causative agent is important to prevent recurrence of anaphylaxis.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s40981-020-00331-w","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T14:02:57Z","timestamp":1586354577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anaphylaxis caused by butylscopolamine bromide: a case report"],"prefix":"10.1186","volume":"6","author":[{"given":"Toshie","family":"Shiraishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuyo","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Takazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"issue":"9","key":"331_CR1","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2165\/00003495-200767090-00007","volume":"67","author":"GN Tytgfat","year":"2007","unstructured":"Tytgfat GN. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs. 2007;67(9):1343\u201357.","journal-title":"Drugs."},{"key":"331_CR2","unstructured":"Essential medicines. World Health Organization.\nhttps:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/. Accessed 19 January, 2017."},{"issue":"3","key":"331_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.legalmed.2005.11.001","volume":"8","author":"H Ikegaya","year":"2006","unstructured":"Ikegaya H, Saka K, Sakurada K, et al. A case of sudden death after intramuscular injection of butylscopolamine bromide. Legal Med. 2006;8(3):194\u20137.","journal-title":"Legal Med."},{"issue":"712","key":"331_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1259\/0007-1285-60-712-417-b","volume":"60","author":"P Treweeke","year":"1987","unstructured":"Treweeke P, Barrett NK. Allergic reaction to Buscopan. Br J Radiol. 1987;60(712):417\u20135.","journal-title":"Br J Radiol."},{"issue":"679","key":"331_CR5","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1136\/pgmj.58.679.316","volume":"58","author":"AC Robinson","year":"1982","unstructured":"Robinson AC, Teeling M. Angioneurotic oedema and uriticaria induced by hyoscine butylbromide. Postgrad Med J. 1982;58(679):3126.","journal-title":"Postgrad Med J."},{"issue":"7","key":"331_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/j.1398-9995.2004.00410.x","volume":"59","author":"R Gonz\u00e1lez-Mendiola","year":"2004","unstructured":"Gonz\u00e1lez-Mendiola R, S\u00e1nchez Fern\u00e1ndez C, Prieto MP. Acute urticaria induced by hyoscine butylbromide. Allergy. 2004;59(7):787\u20138.","journal-title":"Allergy"},{"issue":"4","key":"331_CR7","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.jaip.2018.01.004","volume":"6","author":"DG Ebo","year":"2018","unstructured":"Ebo DG, Faber M, Elst J, et al. In vitro diagnosis of immediate drug hypersensitivity during Anesthesia: a review of the literature. J Allergy Clin Immunol Pract. 2018;6(4):1176\u201384.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"6","key":"331_CR8","first-page":"442","volume":"21","author":"PM Mertes","year":"2011","unstructured":"Mertes PM, Malinovsky JM, Jouffroy L, et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol. 2011;21(6):442\u201353.","journal-title":"J Investig Allergol Clin Immunol."},{"issue":"6","key":"331_CR9","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/all.12142","volume":"68","author":"K Brockow","year":"2013","unstructured":"Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs -- an ENDA\/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702\u201312.","journal-title":"Allergy"},{"issue":"5","key":"331_CR10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1213\/ANE.0000000000002879","volume":"126","author":"T Horiuchi","year":"2018","unstructured":"Horiuchi T, Yokohama A, Orihara M, et al. Usefulness of basophil activation tests for diagnosis of sugammadex-induced anaphylaxis. Anesth Analg. 2018;126(5):1509\u201316.","journal-title":"Anesth Analg"},{"issue":"6","key":"331_CR11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00540-018-2555-z","volume":"32","author":"T Horiuchi","year":"2018","unstructured":"Horiuchi T, Takazawa T, Orihara M, et al. Required cefazolin concentration to maximize diagnostic accuracy of the basophil activation test for cefazolin-induced anaphylaxis. J Anesth. 2018;32(6):797\u2013805.","journal-title":"J Anesth."},{"issue":"5","key":"331_CR12","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/bja\/aev093","volume":"114","author":"T Takazawa","year":"2015","unstructured":"Takazawa T, Horiuchi T, Yoshida N, et al. Flow cytometric investigation of sugammadex-induced anaphylaxis. Br J Anaesth. 2015;114(5):858\u20139.","journal-title":"Br J Anaesth."},{"key":"331_CR13","unstructured":"Pharmaceuticals and Medical Devices Agency. Review reports, prescription drug. http:\/\/www.info.pmda.go.jp\/fsearchnew\/jsp\/menu_fukusayou_base.jsp. Accessed April 2, 2019."},{"issue":"1","key":"331_CR14","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/j.bja.2019.01.002","volume":"123","author":"T Takazawa","year":"2019","unstructured":"Takazawa T, Sabato V, Ebo DG. In vitro diagnostic tests for perioperative hypersensitivity, a narrative review: potential. Limitations, and perspectives. Br J Anaesth. 2019;123(1):e117\u201325.","journal-title":"Br J Anaesth."},{"issue":"1","key":"331_CR15","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/j.bja.2019.04.044","volume":"123","author":"LH Garvey","year":"2019","unstructured":"Garvey LH, Dewachter P, Hepner DL, et al. Management of suspected immediate perioperative allergic reactions: an international overview and consensus recommendations. Br J Anaesth. 2019;123(1):e50\u201364.","journal-title":"Br J Anaesth."}],"container-title":["JA Clinical Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40981-020-00331-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40981-020-00331-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40981-020-00331-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T23:28:10Z","timestamp":1617838090000},"score":1,"resource":{"primary":{"URL":"https:\/\/jaclinicalreports.springeropen.com\/articles\/10.1186\/s40981-020-00331-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["331"],"URL":"https:\/\/doi.org\/10.1186\/s40981-020-00331-w","relation":{},"ISSN":["2363-9024"],"issn-type":[{"type":"electronic","value":"2363-9024"}],"subject":[],"published":{"date-parts":[[2020,4,8]]},"assertion":[{"value":"22 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for publication of this report was obtained from the patient using a form approved by the ethics committee of Yotsuya Medical Cube.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}